LEO Pharma Seeks Start-Ups To Venture ‘Beyond The Pill’
This article was originally published in Clinica
One of Europe’s long-established pharma players in the dermatology market has ring-fenced £45m ($65m) across a three-year period to back start-ups developing non-drug solutions for psoriasis patients. These could include apps, wearables and other technologies and services that could improve management of this autoimmune disease.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.